Showing results (211-220 of 305) with videos related to
Sort By:
Pageof 31
Pflugers Archiv : European Journal of Physiology|June 24, 2022
Fount, fate, features, and function of renal erythropoietin-producing cellsSophie L Dahl, Andreas M Bapst, Stellor Nlandu Khodo, et al.Neuroscience|June 1, 1988
Cholinergic neurons of the chicken ciliary ganglion contain somatostatinM L Epstein, J P Davis, L E Gellman, et al.Clinical Pharmacology and Therapeutics|August 1, 1996
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activityJ A Carrillo, M L Dahl, J O Svensson, et al.British Journal of Clinical Pharmacology|October 27, 2001
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African populationM G Scordo, E Aklillu, U Yasar, et al.Research in Nursing & Health|November 30, 2006
The Discomfort Behavior Scale: a measure of discomfort in the cognitively impaired based on the Minimum Data Set 2.0Karen M Stevenson, Roger L Brown, June L Dahl, et al.Pharmacogenetics|October 1, 1996
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean populationH K Roh, M L Dahl, I Johansson, et al.Journal of Internal Medicine|November 1, 1996
Cyclophosphamide-induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: a causal relationship?L L Gustafsson, L S Eriksson, M L Dahl, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 16, 2001
Role of CYP2C9 polymorphism in losartan oxidationYasar U, G Tybring, M Hidestrand, et al.Clinical Pharmacology and Therapeutics|June 1, 1989
Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beingsM L Dahl-Puustinen, T L Perry, E Dumont, et al.British Journal of Clinical Pharmacology|September 1, 1990
Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypesM L Dahl-Puustinen, C Alm, L Bertilsson, et al.Pageof 31